Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063242 · ClinicalTrials.gov registry record · Phase 2
Sargramostim for Myeloid Dendritic Cell Deficiency
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03063242: Clinical Trial Phase 2 study, sponsored by University of Florida.
NCT03063242 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03063242, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The study will determine whether administration of sargramostim will improve myeloid dendritic cell deficiency in various study groups, including healthy subjects and patients with chronic kidney disease, including those with kidney transplants.
Primary Outcome
mDC levels to \>2.0 x104 mDCs/mL, with the target level defined as levels at or above upper quartile values in healthy controls
Interventions
- BIOLOGICAL Blood samples
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2018-09-17 |
| Phase | Phase 2 |
Why NCT03063242 stopped before completion
NCT03063242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Blood samples is the first listed.
NCT03063242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03063242 about?
NCT03063242 is a clinical study titled "Sargramostim for Myeloid Dendritic Cell Deficiency". The study will determine whether administration of sargramostim will improve myeloid dendritic cell deficiency in various study groups, including healthy subjects and patients with chronic kidney disease, including those with kidney transplants.
What is the current status of trial NCT03063242?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-02-23. Estimated completion is 2018-09-17.
What interventions are being tested in trial NCT03063242?
The interventions under investigation include: Blood samples (BIOLOGICAL), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT03063242?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03063242's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI